Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
Rachael A. Evans, Sabada Dube, Yi Lu, et al.
The Lancet Regional Health - Europe (2023) Vol. 35, pp. 100747-100747
Open Access | Times Cited: 119
Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice
Essy Mozaffari, Aastha Chandak, Robert Gottlieb, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 12, pp. 1626-1634
Open Access | Times Cited: 35
Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic
Valerie W. Shurtleff, M. E. Layton, Craig A. Parish, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3935-3958
Closed Access | Times Cited: 12
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 10
How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19 Pandemic
Michael Boeckh, Steven A. Pergam, Ajit P. Limaye, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 9
Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review
Manuela H Gschwend, Anthony M. Marchese, Dirk Poelaert, et al.
Vaccine (2025) Vol. 49, pp. 126777-126777
Open Access | Times Cited: 1
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 7
Unveiling COVID‐19 treatment strategies for immunocompromised individuals: Therapeutic innovations and latest findings
Li‐Teh Liu, Jih‐Jin Tsai
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 1
Open Access | Times Cited: 6
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity
Raymund R. Razonable
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Spike and nucleocapsid antibody dynamics following SARS‐CoV‐2 infection and vaccination: Implications for sourcing COVID‐19 convalescent plasma from routinely collected blood donations
Clara Di Germanio, Xutao Deng, Brendan G. Balasko, et al.
Transfusion (2024) Vol. 64, Iss. 11, pp. 2063-2074
Open Access | Times Cited: 5
From Emergence to Endemicity: A Comprehensive Review of COVID-19
Roopa Naik, Sreekant Avula, Sujith K Palleti, et al.
Cureus (2023)
Open Access | Times Cited: 11
Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review
Katharine Valéria Saraiva Hodel, Bianca Sampaio Dotto Fiuza, Rodrigo Souza Conceição, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 807-807
Open Access | Times Cited: 4
Prophylactic and therapeutic vaccine development: advancements and challenges
Induni Nayodhara Weerarathna, Elijah Skarlus Doelakeh, Lydia Kiwanuka, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
Seroconversion and dynamics of IgG anti-SARS-CoV-2 antibodies during the pandemic: A two-month observation cohort study on the population of Sleman in Indonesia
Jajah Fachiroh, Septi Kurnia Lestari, Dewi Kartikawati Paramita, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316360-e0316360
Open Access
An ultra-long heavy chain bovine antibody neutralizes SARS-CoV-2 and reacts broadly with sarbecoviruses
Theocharis Tsoleridis, Chengcheng Fan, Emily J. Park, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies
G. Olivieri, Donato Amodio, Emma Concetta Manno, et al.
Vaccine (2025) Vol. 51, pp. 126853-126853
Open Access
The impact of COVID vaccination on incidence of long COVID and healthcare resource utilisation in a primary care cohort in England, 2021–2022
Jingyan Yang, Kiran Rai, Tamuno Alfred, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance
Renato Ferreira‐da‐Silva, Mariana Lobo, Ana Margarida Pereira, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
The Impact of the COVID-19 Omicron Variant on Immunocompromised Patients: ICU Admissions and Increased Mortality
Jan Pander, Fabian Termorshuizen, Dylan W. de Lange, et al.
Infectious Diseases and Therapy (2025)
Open Access
Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults
Natalia E. Castillo Almeida, Lalitha Parameswaran, Elliot DeHaan, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 328-328
Open Access
Antiviral Activity of Halogenated Compounds Derived from L-Tyrosine Against SARS-CoV-2
Paula A. Velásquez-Bedoya, María I. Zapata-Cardona, Laura Milena Monsalve-Escudero, et al.
Molecules (2025) Vol. 30, Iss. 7, pp. 1419-1419
Open Access
Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States
Keya Joshi, Mariia Dronova, Ewelina Paterak, et al.
Infectious Diseases and Therapy (2025)
Open Access
A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants
Maria Laura Cossu, Coral Suero Méndez, Amanda Jackson, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles
Meredith Leston, José M. Ordóñez‐Mena, Mark Joy, et al.
EClinicalMedicine (2025) Vol. 83, pp. 103239-103239
Open Access
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants
Vijay Subramanian
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S34-S45
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top